. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: Curr Med Res Opin. 2016 Mar 2;32(6):991–996. doi: 10.1185/03007995.2016.1149056

Table 4.

Shape and scale parameters of the parametric regression of the log-logistic model on the Kaplan–Meier data.

Therapy	PFS		OS

	Shape (γ)	Scale (λ)	Shape (γ)	Scale (λ)
Pertuzumab + trastuzumab + docetaxel	0.6218719	0.052051	0.5436962	0.019241
Trastuzumab + docetaxel	0.5553811	0.074128	0.576501	0.024996
Capecitabine + lapatinib	0.5161625	0.03389	0.4647835	0.015981
Trastuzumab + lapatinib	0.5538419	0.082315	0.5882669	0.018985
T-DM1	0.6106105	0.104256	0.4743332	0.032557
Trastuzumab + capecitabine	0.0556305	0.115186	0.4513023	0.040966

PFS: progression-free survival; OS: overall survival; T-DM1: trastuzumab emtansine.